|
⚲
|
| Keyboard |
| Ospraie Management LLC
✚
|
|
|---|---|
| CRD # | 305479 |
| SEC # | 801-119728 |
| CIK # | 0001326533, 0001392203 |
| AUM | 1,259.7 M (2026-03-31) |
| Employees | 20 (50% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 212-602-5000 |
| Address | 411 Theodore Fremd Ave Rye, NY 10580 |
| Source | [IAPD] [EDGAR] [Website] [Twitter] [LinkedIn] |
| Total AUM ($B) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
Fees and Compensation Management fees may vary with each client and are explained more fully in each client’s Governing Documents or IMA. Ospraie Management is generally paid a management fee on either a monthly or quarterly basis according to the terms of the relevant agreement with each client. The management fee may be up to 2.0% (annualized) of (i) the net asset value of the shares or interests of each Fund held by investors and certain Managed Accounts, and (ii) the notional value of certain other Managed Accounts. Ospraie Management and/or the General Partners generally receive annual or quarterly performance-based compensation of up to 20% of the realized and unrealized net profits of a Fund or Managed Account as defined and calculated in the applicable Governing Documents or IMA. Certain clients will not bear performance-based compensation on annual (or quarterly) net profits until any respective aggregate net losses from any prior period (or in some instances, legacy investment vehicles) are recovered. OAS has established a profit sharing plan in which affiliates of Ospraie Management will participate based on a percentage of appreciation in the net asset value of OAS over the applicable measurement period subject to an annual hurdle rate. In respect of ORA and Managed Accounts that trade securities, Ospraie or one of its affiliates will participate based on a percentage of appreciation in the net asset value of ORA or such Managed Account over the applicable measurement period. Ospraie Management and/or a General Partner will only receive performance-based compensation if the receipt of such compensation is in compliance with Rule 205-3 under the Investment Advisers Act of 1940, as amended (the “Advisers Act”). Management fees are prorated for partial periods. Performance-based compensation is charged at fiscal year-end (or quarterly, as the case may be) but may be charged during a fiscal year (or quarter) upon the termination of a Managed Account or upon an investor’s redemption from a Fund. Ospraie Management and a General Partner may waive, modify or calculate differently the management fee and any performance- based compensation paid with respect to any client or investor in a Fund on a case-by-case basis. Unless otherwise agreed upon with a client, management fees and performance-based compensation are generally debited directly from Fund accounts and are generally billed to the Managed Accounts. The IMA and account documentation relating to each Managed Account will specify the fees payable to Ospraie Management. Such fees include management fees and performance-based compensation. No Ospraie Management employee is compensated for the sale of securities or other investment products. Ospraie may share a portion of fees with certain placement, sales or referral agents. OAS Transaction Fees Certain affiliates or personnel of Ospraie Management may receive transaction, consulting, advisory, directors’ (including in the form of options or warrants), break-up and other similar fees (collectively, “Transaction Fees”) associated with investments or proposed investments or commitments made by OAS. To the extent that such Transaction Fees are provided to individuals affiliated with Ospraie Management, they will typically not be shared with OAS. Management Offset Fees From time to time, Ospraie Management and certain affiliates receive transaction fees, commitment fees, success fees, syndication fees, financial consulting fees, monitoring fees, advisory fees, break-up fees and similar fees from transactions or proposed transactions with certain portfolio companies in which ORA is invested. In these cases, it is generally Ospraie Management’s policy to allocate the fees to offset the Management Fee payable to Ospraie Management by ORA. Also, from time to time, employees or partners of Ospraie Management serve as directors with respect to portfolio companies in which ORA invests, and compensation is paid to Ospraie Management, its affiliates, or its employees or partners for the provision of the director’s services. In these instances, it is generally Ospraie Management’s policy to allocate compensation received for serving as a director to offset the Management Fee of ORA. Expenses As more fully described in each Fund’s respective Governing Documents and the IMA establishing each Managed Account, the Funds and the Managed Accounts will generally bear expenses in connection with their trading and investment activities, which may include, without limitation, brokerage costs (which vary depending on a number of factors, including the broker utilized for the transaction and any research-related services provided by such broker, the particular security or other instrument traded, and the volume and size of the transaction) (See Item 12 – Brokerage Practices), execution, give-up, exchange, clearing, clearinghouse, principal, and regulatory commissions and fees, delivery, custody, storage, warehousing, and escrow expenses, research fees and expenses (including research subscriptions, expenses related to Bloomberg subscriptions, newsletters, and research fees and expenses paid to advisors or consultants established by former employees of the Manager), fees paid to third-party consultants (including third-party risk management consultants), finder’s fees paid for the introduction of transactions, insurance costs (including directors’ and officers’ insurance, errors and omissions insurance and other similar policies), directors’ fees, professional fees, entity-level taxes, shipping surcharges, customs levies, offloading charges, handling fees, grading fees, assay charges, interest and borrowing charges on margin accounts, borrowed money, investments, and other indebtedness, bank, broker, and dealer service fees, and related expenses and costs. Expenses that are common to multiple clients of Ospraie Management are typically borne by ... |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
Item 7 – Types of Clients Ospraie Management primarily provides investment advice to the Funds and the Managed Accounts, as described above. It may provide investment advisory services to additional clients in the future. Ospraie Management is under no obligation to accept any client and may decline acceptance of a client in its sole discretion. Interests in the Funds are offered on a private placement basis, and where applicable, in reliance on Section 3(c)(7) of the Investment Company Act of 1940, as amended (the “Company Act”), or on another applicable exclusion from the definition of an “investment company” under the Company Act, to persons who generally are “accredited investors” as defined under the Securities Act of 1933, as amended (the “Securities Act”), and “qualified purchasers” as defined under the Company Act, and who are subject to certain other conditions, which are fully set forth in the offering documents of such Funds. At this time, it is not anticipated that Ospraie Management will provide advice to advisory clients that are “retail investors” as defined by Rule 204-5(d)(2) under the Investment Advisers Act of 1940, as amended (“Advisers Act”). Investors in Funds are not Clients of Ospraie Management by virtue of their investment in a Fund. Each Fund’s Governing Documents impose a minimum contribution for investment, which varies from Fund to Fund, and is subject to Ospraie Management’s sole discretion to accept contributions in lesser amounts. Ospraie Management may waive the minimum investment or contribution amount with respect to any Client in its sole discretion. In order to invest in a Fund that is subject to a performance fee, an investor must be a “qualified client” as defined by Section 205 of the Advisers Act, and Rule 205-3 thereunder. |
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| Other | ORA Battle Swine LLC | 2025-03-28 | 27.2 M | |
| PE | Ospraie Real Assets Fund LP | [2024-03-28] | 1,248.2 M | 879.8 M |
| Offered $1,248,195,264 · Filed 2023-06-30 (D) · Exemption 506(b), 3(c), 3(c)(7) · Duration More than one year · Revenue Decline to Disclose | ||||
| VC | Ospraie AG Science LLC | [2019-10-02] | 237.1 M | 85.6 M |
| Filed 2025-09-05 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| HF | Ospraie Equity Fund LP | [2012-03-29] | 77.5 M | 59.9 M |
| Filed 2012-08-15 (D/A) · Exemption 506, 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Ospraie Equity Fund Ltd | [2012-03-29] | 2.5 M | 6.5 M |
| Filed 2012-08-15 (D/A) · Exemption 506, 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Ospraie Equity Master Fund LP | 2012-03-29 | 78.1 M | |
| PE | Ospraie Special Opportunities LP | 2012-03-29 | 40.0 M | |
| PE | Ospraie Special Opportunities Master Alternative Holdings LLC | 2012-03-29 | 7.6 M | |
| PE | Ospraie Special Opportunities Master Holdings Ltd | 2012-03-29 | 96.5 M | |
| PE | Ospraie Special Opportunities Offshore Ltd | [2012-03-29] | 69.7 M | |
| HF | Permal Ospraie Ltd Class E | 2012-03-29 | 18.0 M | |
| HF | The Ospraie Fund LP | 2012-03-29 | 71.7 M | |
| HF | The Ospraie Fund Ltd | 2012-03-29 | 168.6 M | |
| HF | The Ospraie Portfolio Ltd | 2012-03-29 | 68.8 M | |
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 3 | 1.2 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 1 | 0.1 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 1 | 0.0 |
| Total | 5 | 1.3 |
| By Discretionary | ||
| Discretionary | 4 | 1.3 |
| Non-Discretionary | 1 | 0.0 |
| Total | 5 | 1.3 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 1.3 | |
| Total | 5 | 1.3 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Gary Linford | Director | 176 | 42 | |
| John Lewis | Director | 289 | 39 | |
| Dwight Anderson | Executive Officer | 7 | 2 | |
| Ospraie Management LLC | Promoter | 6 | 2 | |
| Ospraie Group II LLC | Executive Officer | 3 | 2 | |
| Nathan Ebeling | Promoter | 2 | 2 | |
| Ospraie Real Assets GP LLC | Executive Officer | 1 | 1 | |
| Oas MM LLC | Executive Officer | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001326533] | |
| 3 | [0001326533] | |
| 4 | [0001326533] | |
| 3 | [0001392203] | |
| 4 | [0001392203] |
| Firm Profile (Form ADV) | |
|---|---|
| Clients | 6 |
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| LEI | 549300BVQ8NJ3V9UIN21 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Marrone Bio Innovations Inc MBII
Common Stock, $0.00001 par value
|
2022-07-12 | Tender | 70,836,258 | ||
|
Marrone Bio Innovations Inc MBII
Warrant · derivative
|
2021-12-15 | Option exercise | 3,553,583 | ||
|
Marrone Bio Innovations Inc MBII
Common Stock, $0.00001 par value
|
2021-12-15 | Option exercise | 3,553,583 | $0.75 | 2,665,187 |
|
Marrone Bio Innovations Inc MBII
Warrant · derivative
|
2021-03-15 | Option exercise | 4,264,299 | ||
|
Marrone Bio Innovations Inc MBII
Common Stock, $0.00001 par value
|
2021-03-15 | Option exercise | 4,264,299 | $0.75 | 3,198,224 |
|
Marrone Bio Innovations Inc MBII
Common Stock, $0.00001 par value
|
2020-12-15 | Option exercise | 9,476,221 | $0.75 | 7,107,166 |
|
Marrone Bio Innovations Inc MBII
Warrant · derivative
|
2020-12-15 | Option exercise | 9,476,221 | ||
|
Marrone Bio Innovations Inc MBII
Warrant · derivative
|
2020-09-15 | Option exercise | 1,974,213 | ||
|
Marrone Bio Innovations Inc MBII
Common Stock, $0.00001 par value
|
2020-09-15 | Option exercise | 1,974,213 | $0.75 | 1,480,660 |
|
Marrone Bio Innovations Inc MBII
Warrant · derivative
|
2020-05-01 | Option exercise | 2,467,766 | ||
|
Marrone Bio Innovations Inc MBII
Common Stock, $0.00001 par value
|
2020-05-01 | Option exercise | 2,467,766 | $0.75 | 1,850,824 |
|
Marrone Bio Innovations Inc MBII
Warrant · derivative
|
2020-04-29 | Grant | 2,467,766 | ||
|
Marrone Bio Innovations Inc MBII
Warrant · derivative
|
2020-04-29 | Disposed to issuer | 5,027,325 | ||
|
Marrone Bio Innovations Inc MBII
Warrant · derivative
|
2020-04-29 | Disposed to issuer | 12,233,158 | ||
|
Marrone Bio Innovations Inc MBII
Warrant · derivative
|
2020-04-29 | Disposed to issuer | 8,378,871 | ||
|
Marrone Bio Innovations Inc MBII
Warrant · derivative
|
2020-04-29 | Disposed to issuer | 3,351,542 | ||
|
Marrone Bio Innovations Inc MBII
Warrant · derivative
|
2020-04-29 | Grant | 1,974,213 | ||
|
Marrone Bio Innovations Inc MBII
Warrant · derivative
|
2020-04-29 | Grant | 3,553,583 | ||
|
Marrone Bio Innovations Inc MBII
Warrant · derivative
|
2020-04-29 | Grant | 4,264,299 | ||
|
Marrone Bio Innovations Inc MBII
Warrant · derivative
|
2020-04-29 | Grant | 9,476,221 | ||
| showing 20 of 33 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
FCO Advisors LP
✚
|
NY | 1,339.3 M |
|
Chilton Investment Company Inc
✚
|
CT | 1,323.2 M |
|
Framework Ventures Management LLC
✚
|
CA | 1,280.9 M |
|
PFM Health Sciences LP
✚
|
CA | 1,266.8 M |
|
WEBS Creek Capital Management LP
✚
|
TX | 1,254.4 M |
|
Seven Grand Managers LLC
✚
|
NY | 1,235.3 M |
|
Wynkoop LLC
✚
|
CO | 1,217.3 M |
|
Hudson Cove Capital Management LLC
✚
|
NJ | 1,213.5 M |
|
Arlon Advisor LLC
✚
|
NY | 1,176.7 M |
|
Octagon Capital Advisors LP
✚
|
NY | 1,175.3 M |